Compare RPD & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPD | NBTX |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2015 | 2020 |
| Metric | RPD | NBTX |
|---|---|---|
| Price | $12.65 | $21.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 1 |
| Target Price | ★ $22.40 | $8.00 |
| AVG Volume (30 Days) | ★ 1.1M | 36.0K |
| Earning Date | 02-10-2026 | 09-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $858,667,000.00 | $11,930,711.00 |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $1.58 | $145.24 |
| P/E Ratio | $36.31 | ★ N/A |
| Revenue Growth | ★ 3.08 | N/A |
| 52 Week Low | $12.61 | $2.93 |
| 52 Week High | $40.25 | $30.35 |
| Indicator | RPD | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 22.20 | 49.74 |
| Support Level | $13.22 | $19.61 |
| Resistance Level | $13.97 | $22.22 |
| Average True Range (ATR) | 0.53 | 1.05 |
| MACD | -0.18 | -0.06 |
| Stochastic Oscillator | 0.32 | 46.32 |
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.